57912-35-3 Usage
Uses
Used in Biochemistry:
Z-CYS(Z)-OH is used as a protected amino acid in peptide synthesis for the creation of custom peptides with specific sequences and structures. The protecting group ensures that the cysteine residue does not participate in unwanted side reactions, allowing for the controlled formation of disulfide bonds and the synthesis of complex peptide structures.
Used in Pharmaceutical Industry:
Z-CYS(Z)-OH is used as a key component in the development of therapeutic peptides and proteins. Its role in the synthesis of bioactive molecules with specific functions makes it valuable for the design and production of drugs targeting various diseases and conditions.
Used in Biotechnology:
Z-CYS(Z)-OH is utilized as a building block for the engineering of recombinant proteins and the development of biotechnological applications. Its ability to form disulfide bonds contributes to the stability and functionality of engineered proteins, making it an essential tool in the biotechnology sector.
Check Digit Verification of cas no
The CAS Registry Mumber 57912-35-3 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,7,9,1 and 2 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 57912-35:
(7*5)+(6*7)+(5*9)+(4*1)+(3*2)+(2*3)+(1*5)=143
143 % 10 = 3
So 57912-35-3 is a valid CAS Registry Number.
InChI:InChI=1/C19H19NO6S/c21-17(22)16(20-18(23)25-11-14-7-3-1-4-8-14)13-27-19(24)26-12-15-9-5-2-6-10-15/h1-10,16H,11-13H2,(H,20,23)(H,21,22)/t16-/m0/s1
57912-35-3Relevant academic research and scientific papers
Inhibition of farnesyltransferase
-
, (2008/06/13)
Peptidomimetics of the formula C-AMBA-X where C is cysteine, X is, for example, methionine or phenylalanine and AMBA is a hydrophobic spacer, notably 3-aminomethylbenzoic acid. These compounds are effective inhibitors of p21 ras farnesyltransferase. Other modifications including alternative spacers for AMBA, and replacement of the A1 A2 X component of known CA1 A2 X tetrapeptides by a non-peptide aryl or heterocyclic component are also disclosed as are various phosphonylated and arylated derivatives of peptides and peptidomimetics. Pro-drugs made by functionalizing terminal amino and carboxylic acid groups of peptides and peptidomimetics are also disclosed. Such functionalized derivatives demonstrate increased cell uptake. Other structural modifications are also referred to.